Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00874211 · ClinicalTrials.gov registry record
S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases
A clinical trial, sponsored by SWOG Cancer Research Network.
- Completed
- Registry status
- 3,571
- Enrollment target
NCT00874211 is a clinical trial that has completed, run by SWOG Cancer Research Network. The registered enrollment target is 3,571 participants.
The verdict
NCT00874211 has completed, sponsored by SWOG Cancer Research Network.
- COMPLETED
- Registry status
- 3,571 participants
- Enrollment target
Study Summary
RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care. PURPOSE: This clinical trial is studying osteonecrosis of the jaw in patients with cancer who are receiving zoledronic acid for bone metastases.
Interventions
- PROCEDURE assessment of therapy complications
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,571 participants |
| Start Date | 2008-12 |
| Est. Completion | 2019-06 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00874211
The ClinicalTrials.gov registry entry for NCT00874211 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 3,571 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SWOG Cancer Research Network, which has 270 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which assessment of therapy complications is the first listed.
NCT00874211 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00874211 about?
NCT00874211 is a clinical study titled "S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases". RATIONALE: Gathering information about how often osteonecrosis of the jaw occurs in patients receiving zoledronic acid for bone metastases may help doctors learn more about the disease and provide the best follow-up care. PURPOSE: This clinical trial is studying osteonecrosis of the jaw in patients...
What is the current status of trial NCT00874211?
This trial is currently completed. The enrollment target is 3,571 participants. The study started on 2008-12. Estimated completion is 2019-06.
What interventions are being tested in trial NCT00874211?
The interventions under investigation include: assessment of therapy complications (PROCEDURE).
Who is sponsoring clinical trial NCT00874211?
This trial is sponsored by SWOG Cancer Research Network, which has 270 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.